secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-205079
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio reports positive SC formulation data; ITP data June 2026, pMN/SLE Q4 2026
--------------------------------------------------------------------------------

- Topline Phase 1 SC data: robust B-cell depletion similar to IV; generally safe and well-tolerated.
- Fast Track Designation received for primary membranous nephropathy (pMN).
- Initial ITP Phase 1b/2a data from low-dose cohort expected June 2026.
- Initial pMN Phase 2 and SLE Phase 1b data expected Q4 2026.
- Budoprutug is an anti-CD19 mAb targeting B-cell mediated diseases; trials enrolling to plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526205079/0001193125-26-205079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526205079/d127757d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-205079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer